PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials

BACKGROUND: Paclitaxel and carboplatin is the standard chemotherapy for the treatment of advanced or recurrent endometrial cancer. However, the benefit of adding programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors to chemotherapy is still unclear. METHOD: We searched PubMed,...

Descripción completa

Detalles Bibliográficos
Autores principales: de Moraes, Francisco Cezar Aquino, Pasqualotto, Eric, Lopes, Lucca Moreira, Cavalcanti Souza, Maria Eduarda, de Oliveira Rodrigues, Anna Luíza Soares, de Almeida, Artur Menegaz, Stecca, Carlos, Fernandes, Marianne Rodrigues, dos Santos, Ney Pereira Carneiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688003/
https://www.ncbi.nlm.nih.gov/pubmed/38031003
http://dx.doi.org/10.1186/s12885-023-11654-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688003/
https://www.ncbi.nlm.nih.gov/pubmed/38031003
http://dx.doi.org/10.1186/s12885-023-11654-z

Ejemplares similares